Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Akari Therapeutics ADR (AKTX)

Akari Therapeutics ADR (AKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer GlobeNewswire - Tue Dec 9, 7:40AM CST

Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival...

AKTX : 0.3894 (-5.02%)
Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment GlobeNewswire - Thu Dec 4, 8:00AM CST

Access the Akari CEO Corner  here TAMPA, Fla. and LONDON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads...

AKTX : 0.3894 (-5.02%)
Akari Therapeutics Announces Release of the Next CEO Corner Segment GlobeNewswire - Tue Nov 25, 8:00AM CST

Access the Akari CEO Corner  here BOSTON and LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for...

AKTX : 0.3894 (-5.02%)
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer GlobeNewswire - Tue Nov 18, 7:35AM CST

TAMPA and LONDON, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced...

AKTX : 0.3894 (-5.02%)
Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors GlobeNewswire - Mon Nov 10, 7:30AM CST

Data presented at the 40 th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity...

AKTX : 0.3894 (-5.02%)
Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available GlobeNewswire - Tue Nov 4, 8:25AM CST

BOSTON and LONDON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced...

AKTX : 0.3894 (-5.02%)
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP GlobeNewswire - Thu Oct 30, 7:35AM CDT

BOSTON and LONDON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced...

AKTX : 0.3894 (-5.02%)
Akari Therapeutics Announces Launch of CEO Corner Platform GlobeNewswire - Wed Oct 22, 8:05AM CDT

CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties with the ability to ask questions and submit topics for...

AKTX : 0.3894 (-5.02%)
Akari Therapeutics Announces $2.5 Million Direct Offering Tipranks - Fri Oct 17, 8:50AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Akari Therapeutics...

AKTX : 0.3894 (-5.02%)
Akari Therapeutics Announces $2.5 Million Registered Direct Offering GlobeNewswire - Wed Oct 15, 7:30AM CDT

BOSTON and LONDON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs),...

AKTX : 0.3894 (-5.02%)

Barchart Exclusives

Inflation Data, AI Earnings and Other Can't Miss Items this Week Barchart - Sun Dec 14, 12:00PM CST
Markets enter a critical week still reeling from Friday's sharp selloff in technology and AI stocks following disappointing reactions to Oracle and Broadcom earnings that raised questions about AI infrastructure spending sustainability and return on massive capital investments. Here are 5 things to watch this week in the Market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot